miRoncol Health introduces miCheckup, a novel miRNA-based blood test designed to detect early-stage cancer signals, expanding the landscape of Canadian diagnostic screening options.
miRoncol Health has officially launched miCheckup, marking the introduction of Canada's first commercially available miRNA-based blood test for multi-cancer screening. This milestone positions the company as a pioneer in early-stage cancer detection, leveraging proprietary miRNA technology to identify signals that may indicate the presence of malignancy.
miCheckup is Canada's first commercially available miRNA-based blood test designed for multi-cancer screening.
Patients who receive a positive signal from the miCheckup test are required to undergo a whole-body MRI follow-up.
miRoncol Health has officially launched miCheckup, the first commercially available miRNA-based blood test for multi-cancer screening in Canada. The diagnostic tool identifies signals associated with early-stage cancer, marking a significant milestone for the company's clinical portfolio and Canadian oncology diagnostics.
miCheckup is a blood-based diagnostic test developed by miRoncol Health that uses miRNA technology to screen for signals linked to early-stage cancer.
The test is currently available in Canada, marking the first time a miRNA-based multi-cancer screening tool has been commercially launched in the country.